Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kazia Therapeutics Ltd director Robert F. Apple received a grant of stock options over 75,000 ADSs on January 8, 2026. The options have an exercise price of $6.78 per ADS, were granted for no cash consideration, and vest on January 8, 2027. They expire on January 8, 2029, and represent his full reported option holdings from this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
APPLE ROBERT F
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 75,000 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 75,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 75,000 options
Exercise price: $6.78 per ADS
Holdings after grant: 75,000 derivative securities
+3 more
6 metrics
Option grant size
75,000 options
Employee stock option award over ADSs to director
Exercise price
$6.78 per ADS
Set by reference to Nasdaq closing price on January 8, 2026
Holdings after grant
75,000 derivative securities
Total stock options reported following this transaction
Grant date
January 8, 2026
Board-approved option award date
Vesting date
January 8, 2027
Date when options become exercisable
Expiration date
January 8, 2029
Date when options expire if unexercised
Key Terms
Employee Stock Option, ADSs, Remuneration Committee, exercise price
4 terms
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
ADSs financial
"underlying_security_title: "ADSs" and options over ADSs"
Remuneration Committee financial
"approved by the Remuneration Committee on January 8, 2026"
A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.
exercise price financial
"at an exercise price of $6.78 per ADS"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What insider transaction did Kazia Therapeutics (KZIA) report for Robert F. Apple?
Kazia Therapeutics reported that director Robert F. Apple received an award of 75,000 stock options over ADSs. The grant is compensation-related, not an open-market purchase or sale, and was approved by the board’s Remuneration Committee on January 8, 2026.
What is the exercise price of Robert F. Apple’s new Kazia (KZIA) stock options?
The stock options granted to Robert F. Apple have an exercise price of $6.78 per ADS. This price was set by reference to the closing price of Kazia’s ADSs on Nasdaq on January 8, 2026, aligning the award with the market level that day.
How many Kazia Therapeutics (KZIA) ADSs are covered by Robert F. Apple’s option grant?
The award covers options over 75,000 Kazia Therapeutics ADSs. Following this grant, the filing shows 75,000 derivative securities held, all tied to this single employee stock option award reported as directly owned by the director.
When do Robert F. Apple’s Kazia (KZIA) stock options vest and expire?
The options granted to Robert F. Apple vest on January 8, 2027, one year after approval. They expire on January 8, 2029, providing a two-year exercise window after vesting for the director to decide whether to exercise the award.
Did Robert F. Apple pay consideration for his Kazia Therapeutics (KZIA) option grant?
No, the filing states the options were granted for no consideration. This means the director did not pay cash to receive the 75,000-option award; any cost arises only if he later exercises at the $6.78 per ADS exercise price.